Mineralys Therapeutics Balance Sheet
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mineralys Therapeutics financial position
At the end of fiscal 2025, Mineralys Therapeutics reported total assets of $661.8 million, up 221.4% from a year earlier against total liabilities of $15.1 million. Shareholders' equity stood at $646.7 million, or 97.7% of assets. The company held $172.9 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 43.76, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Mineralys Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 |
|---|---|---|---|---|
| Cash & Equivalents | 172.92M | 114.09M | 49.30M | 87.70M |
| Total Current Assets | 661.39M | 205.35M | 249.10M | 112.81M |
| Property, Plant & Equipment | 38.00K | 53.00K | 0 | — |
| Long-Term Investments | — | 0 | 2.48M | — |
| Total Assets | 661.81M | 205.90M | 251.64M | 114.44M |
| Accounts Payable | 2.02M | 479.00K | 601.00K | 1.91M |
| Total Current Liabilities | 15.11M | 14.65M | 10.48M | 8.07M |
| Total Liabilities | 15.11M | 14.65M | 10.48M | 166.71M |
| Shareholders' Equity | 646.69M | 191.26M | 241.15M | -52.27M |
| Retained Earnings | -457.17M | -302.52M | -124.71M | -52.81M |
| Net Cash (Debt) | 172.92M | 114.09M | 49.30M | 87.70M |
| Shares Outstanding | 81.54M | 49.82M | 41.13M | 6.42M |
This table shows 4 annual periods of Mineralys Therapeutics's balance sheet, from FY 2025 back to FY 2022, across 12 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow MLYS's reporting calendar. What is a balance sheet?